Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc. For the three and nine months ended September 30, 2023 ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) September 30, December 31, As at 2023 2022 Assets Current assets Cash and cash equivalents (note 4) $ 39,981 $ 11,666 Marketable securities — 20,472 Other receivables (note 4) 630 521 Prepaid expenses (note 4) 4 ...